Profile data is unavailable for this security.
About the company
Shanghai OPM Biosciences Co Ltd is a China-based company mainly engaged in cell culture products and services. The Company's main business involves two application areas: cell culture medium series products and biopharmaceutical contract development and production services. The Company's cell culture medium series products are widely used in the production of biological products such as protein/antibody production, vaccine production, cell therapy/gene therapy, and others. The Company's antibody drug development contract development and manufacturing organization (CDMO) service platform is committed to providing domestic and foreign customers with full-process services from antibody engineering humanization screening, cell line construction, process development to pilot production and clinical I&II phase sample production.
- Revenue in CNY (TTM)352.91m
- Net income in CNY43.24m
- Incorporated2013
- Employees328.00
- LocationShanghai OPM Biosciences Co LtdBlock 28Lane 908, Ziping Road, Pudong New AeraSHANGHAI 201321ChinaCHN
- Phone+86 2 120780178
- Fax+86 2 168101069
- Websitehttps://www.opmbiosciences.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Konruns Pharmaceutical Co Ltd | 871.31m | 57.12m | 6.86bn | 668.00 | 122.68 | 2.15 | -- | 7.87 | 0.3515 | 0.3515 | 5.55 | 20.06 | 0.2166 | 1.58 | 2.86 | 1,304,353.00 | 0.8033 | 3.82 | 0.9658 | 4.45 | 89.11 | 88.68 | 3.71 | 16.16 | 2.98 | -- | 0.0745 | 31.72 | -10.28 | -4.99 | -71.94 | -30.80 | 40.67 | -- |
| Shanghai Haixin Group Co Ltd | 788.05m | 156.25m | 6.97bn | 715.00 | 63.29 | 2.12 | -- | 8.84 | 0.1294 | 0.1294 | 0.6529 | 3.87 | 0.1404 | 5.99 | 8.40 | 1,102,168.00 | 3.13 | 2.89 | 3.42 | 3.27 | 51.52 | 46.43 | 22.33 | 12.82 | 4.42 | -- | 0.0209 | 35.43 | -32.70 | -6.47 | -9.09 | 7.75 | -34.08 | 5.92 |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 711.63m | -62.67m | 7.07bn | 925.00 | -- | 3.98 | -- | 9.94 | -0.0605 | -0.0605 | 0.6865 | 2.18 | 0.2795 | 2.02 | 2.18 | 769,331.60 | -2.47 | 5.01 | -2.70 | 6.20 | 88.90 | 91.92 | -8.83 | 14.50 | 8.51 | -11.45 | 0.007 | 48.29 | -16.61 | -7.17 | -63.42 | -29.45 | 1.11 | -- |
| Jiangsu Aidea Pharmaceutical Group Co Ld | 671.33m | -87.10m | 7.11bn | 704.00 | -- | 7.27 | -- | 10.59 | -0.207 | -0.207 | 1.60 | 2.32 | 0.3558 | 1.01 | 4.33 | 953,592.70 | -3.23 | -4.33 | -5.23 | -5.36 | 63.08 | 40.16 | -9.09 | -20.35 | 1.03 | -2.12 | 0.3093 | -- | 1.57 | 3.89 | -85.63 | -- | 5.88 | -- |
| Shanghai OPM Biosciences Co Ltd | 352.91m | 43.24m | 7.32bn | 328.00 | 150.01 | 3.04 | -- | 20.73 | 0.3751 | 0.3751 | 3.18 | 18.51 | 0.1558 | 2.50 | 4.05 | 1,075,953.00 | 1.88 | 3.50 | 1.96 | 3.69 | 50.40 | 57.44 | 12.09 | 21.40 | 15.47 | -- | 0.0272 | 58.30 | 22.26 | 38.41 | -61.04 | -- | 43.46 | -- |
| Wuhan Keqian Biology Co Ltd | 1.01bn | 459.54m | 7.64bn | 924.00 | 16.74 | 1.83 | -- | 7.54 | 0.9796 | 0.9796 | 2.16 | 8.95 | 0.2209 | 2.86 | 3.23 | 1,097,706.00 | 9.97 | 11.71 | 11.17 | 13.56 | 65.26 | 73.57 | 45.16 | 44.51 | 5.02 | -- | 0.0017 | 32.23 | -11.48 | 13.17 | -3.43 | 9.52 | -4.93 | -- |
| Lushang Freda Pharmaceutical Co Ltd | 3.78bn | 214.11m | 7.71bn | 3.63k | 35.90 | 1.84 | -- | 2.04 | 0.2112 | 0.2112 | 3.72 | 4.12 | 0.633 | 3.37 | 7.63 | 1,040,448.00 | 4.45 | 0.7994 | 6.29 | 5.29 | 51.41 | 23.96 | 7.02 | 3.71 | 3.96 | -- | 0.0393 | 43.21 | -13.02 | -17.29 | -19.73 | -6.70 | 21.16 | 0.00 |
| Cisen Pharmaceutical Co Ltd | 3.56bn | 492.80m | 7.92bn | 3.30k | 16.14 | 1.29 | -- | 2.22 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
Data as of Feb 10 2026. Currency figures normalised to Shanghai OPM Biosciences Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
21.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 2025 | 5.70m | 5.01% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 4.31m | 3.79% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 3.10m | 2.72% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 2.90m | 2.55% |
| Shanghai HFT Fortune Asset Management Co. Ltd.as of 30 Jun 2025 | 2.53m | 2.23% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 2.47m | 2.17% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 1.48m | 1.30% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2025 | 1.29m | 1.13% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 1.08m | 0.95% |
| Huashang Fund Management Co., Ltd.as of 30 Jun 2025 | 142.96k | 0.13% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
